Reverse Transcriptase News and Research

RSS
FDA approves Gilead's Complera for treatment of HIV-1 infection

FDA approves Gilead's Complera for treatment of HIV-1 infection

Janssen presents EDURANT 96-week Phase 3 trial data at International AIDS Society Conference

Janssen presents EDURANT 96-week Phase 3 trial data at International AIDS Society Conference

ISENTRESS demonstrates comparable efficacy to efavirenz in treatment-naïve adult HIV-1 patients

ISENTRESS demonstrates comparable efficacy to efavirenz in treatment-naïve adult HIV-1 patients

HIV drug linked to accelerated and early aging

HIV drug linked to accelerated and early aging

Some HIV drugs can cause premature ageing

Some HIV drugs can cause premature ageing

FDA approves second anti-HIV drug from Rutgers-Janssen collaboration

FDA approves second anti-HIV drug from Rutgers-Janssen collaboration

Edurant receives FDA approval for treatment of HIV-1 infection

Edurant receives FDA approval for treatment of HIV-1 infection

Study questions suitability of anti-retroviral drugs for the young

Study questions suitability of anti-retroviral drugs for the young

Rate of antiretroviral virological failure higher among children living with HIV/AIDS than adults, study finds

Rate of antiretroviral virological failure higher among children living with HIV/AIDS than adults, study finds

Adamis acquires cancer vaccine technology from UCSD

Adamis acquires cancer vaccine technology from UCSD

Increased risk of virologic failure associated with NNRTI-based regimens in HIV-1 drug resistance mutations

Increased risk of virologic failure associated with NNRTI-based regimens in HIV-1 drug resistance mutations

FDA approves Matrix NDA for Zidovudine Tablets

FDA approves Matrix NDA for Zidovudine Tablets

Viruses that are natural part of human genome may retrovirus culprit

Viruses that are natural part of human genome may retrovirus culprit

Genomic Health to present prostate cancer studies at ASCO Genitourinary Cancer Symposium

Genomic Health to present prostate cancer studies at ASCO Genitourinary Cancer Symposium

Gilead resubmits NDA for single-tablet regimen of Truvada/TMC278

Gilead resubmits NDA for single-tablet regimen of Truvada/TMC278

Idenix announces updates on HCV and HIV clinical development programs

Idenix announces updates on HCV and HIV clinical development programs

Shionogi-ViiV Healthcare initiates 572-Trii fixed-dose combination therapy study for HIV

Shionogi-ViiV Healthcare initiates 572-Trii fixed-dose combination therapy study for HIV

Simple hTERT analysis may provide useful prognostic tool in advanced non-small cell lung cancer

Simple hTERT analysis may provide useful prognostic tool in advanced non-small cell lung cancer

Johnson & Johnson deal may bring HIV/AIDS drugs to developing countries faster

Johnson & Johnson deal may bring HIV/AIDS drugs to developing countries faster

Tibotec grants multiple non-exclusive licenses to generic manufacturers for rilpivirine hydrochloride

Tibotec grants multiple non-exclusive licenses to generic manufacturers for rilpivirine hydrochloride